This is the largest weight loss reported in any retatrutide Phase 3 trial to date and forms the basis of Lilly's obesity regulatory submission
Source: Coskun et al., The Lancet 2022 Phase 2 Results Phase 2 -- Obesity (NEJM 2023) NCT04881760 | Published: New England Journal of Medicine , 2023 (Jastreboff AM, et al.) This was the landmark Phase 2 trial that put retatrutide on the map
Delivery methods other than injections and oral pills, such as sublingual drops and dissolving tablets, have not been tested in clinical trials
In addition, all currently available GLP-1R therapies are peptide agonists, most of which require subcutaneous administration [140]
Following reconstitution with Bacteriostatic Water, keep refrigerated and minimize repeated freeze-thaw cycles
Our GLP-1 Medications are available at all Elevated Health Clinics.